Antipsychotic Polypharmacy and Associated Phenomena in Patients with Schizophrenia: Rational or Irrational?

Chapter

Abstract

A review of the literature of psychopharmacological studies reveals that there are great discrepancies in reported rates of psychotropic drug utilization patterns. As newer psychotropic agents are being introduced into the market, it is necessary to assess the prescribing patterns within specific local contexts, clinical factors associated with their use and their change over time. In the first psychopharmacological study of antipsychotic prescription patterns for schizophrenia in six East Asian countries and regions in 2001 (REAP-I), it was found that the second-generation antipsychotics (SGA) were generally under-utilized and Japan had a relatively higher dose and antipsychotic polypharmacy whilst China had a higher prescription of clozapine. A second study (REAP-II) was undertaken in 2004 and trends of increasing SGA use with reciprocal decreasing use of first generation antipsychotics (FGA) among the East Asian countries were noted. The current study aims to examine prescription patterns of psychotropic drugs, relevant associated factors with antipsychotic polypharmacy (defined as prescription of two or more antipsychotics) and their inter-relationships with associated phenomena such as long acting antipsychotic use, prescription of FGA and SGA medications within a tertiary psychiatric hospital setting in Singapore.

We conducted a cross-sectional pharmaco-epidemiological survey of psychotropic prescription patterns for 100 hospitalized patients with schizophrenia. Data collection was performed using a standardized protocol which included patient’s social and clinical characteristics, psychiatric symptoms, course of illness, and information about medications including types of drugs, dosages and adverse effects.

Antipsychotic polypharmacy (74% of subjects) was associated with greater prescription of long acting antipsychotic, FGA use, higher antipsychotic dose and lower Brief Psychotic Rating Scale scores. Use of long acting antipsychotic was associated with older age group, less likelihood of SGA use, greater likelihood of antipsychotic polypharmacy, anticholinergic use and use of higher dosage of antipsychotic. Prescription of FGAs was associated with older age, verbal aggression, a higher total daily chlorpromazine equivalent dosage, higher rates of antipsychotic polypharmacy and lesser use of SGA. SGA prescription was associated with younger age, less prescriptions of anticholinergic and long acting antipsychotic medications but not antipsychotic polypharmacy.

We observed significant rates of antipsychotic polypharmacy but also in the use of SGA and prescription of low antipsychotic doses. The importance having regular psychotropic prescription audits and follow up studies may allow evaluation of all patterns of antipsychotic use including polypharmacy, promote understanding of contextual prescription trends and encourage consideration of rational prescription practices including antipsychotic polypharmacy.

Keywords

Mood Stabilizer Brief Psychiatric Rate Scale East Asian Country Verbal Aggression Extrapyramidal Side Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Abbreviations

BPRS

Brief Psychiatric Rating Scale

FGAs

First generation antipsychotics

GAF

Global Assessment of Functioning Scale

SGAs

Second generation antipsychotics

Notes

Acknowledgements

We would like to thank all the patients who participated in the study as well as all the hospital staff that supported this project.

References

  1. 1.
    Bitter I, Chou JC, Ungvari GS et al (2003) Prescribing for inpatients with schizophrenia: an international multi-center comparative study. Pharmacopsychiatry 36(4):143–149PubMedCrossRefGoogle Scholar
  2. 2.
    Kane JM, Leucht S, Carpenter D et al (2003) The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 64(Suppl 12):5–19PubMedGoogle Scholar
  3. 3.
    Suarez D, Haro JM (2008) Overview of the findings from the European SOHO study. Expert Rev Neurother 8(6):873–880PubMedCrossRefGoogle Scholar
  4. 4.
    Parish PA (1973) Drug prescribing – the concern of all. R Soc Health J 93(4):213–217PubMedCrossRefGoogle Scholar
  5. 5.
    Hemminki E (1975) Review of literature on the factors affecting drug prescribing. Soc Sci Med 9(2):111–116PubMedCrossRefGoogle Scholar
  6. 6.
    Parish PA (1973) What influences have led to increased prescribing of psychotropic drugs? J R Coll Gen Pract 23(Suppl 2):49–58PubMedGoogle Scholar
  7. 7.
    Martin K, Begaud B, Latry P et al (2004) Differences between clinical trials and postmarketing use. Br J Clin Pharmacol 57(1):86–92PubMedCrossRefGoogle Scholar
  8. 8.
    Verdoux H, Tournier M, Cougnard A et al (2006) Pharmacoepidemiology of psychotropic medication: utilisation and impact in real-life conditions. Therapie 61(1):17–22PubMedCrossRefGoogle Scholar
  9. 9.
    Kane JM, Freeman HL (1994) Towards more effective antipsychotic treatment. Br J Psychiatry Suppl 25:22–31PubMedGoogle Scholar
  10. 10.
    Committee WE (1977) The selection of essential drugs (Technical report series 615). World Health Organization, GenevaGoogle Scholar
  11. 11.
    Bowers L, Callaghan P, Clark N et al (2004) Comparisons of psychotropic drug prescribing patterns in acute psychiatric wards across Europe. Eur J Clin Pharmacol 60(1):29–35PubMedCrossRefGoogle Scholar
  12. 12.
    Rothbard AB, Kuno E, Foley K (2003) Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia. Schizophr Bull 29(3):531–540PubMedCrossRefGoogle Scholar
  13. 13.
    Sim K, Su A, Fujii S et al (2004) Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. Br J Clin Pharmacol 58(2):178–183PubMedCrossRefGoogle Scholar
  14. 14.
    Bollini P, Pampallona S, Orza MJ et al (1994) Antipsychotic drugs: is more worse? A meta-analysis of the published randomized control trials. Psychol Med 24(2):307–316PubMedCrossRefGoogle Scholar
  15. 15.
    Faries D, Ascher-Svanum H, Zhu B et al (2005) Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry 5:26PubMedCrossRefGoogle Scholar
  16. 16.
    Freudenreich O, Goff DC (2002) Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand 106(5):323–330PubMedCrossRefGoogle Scholar
  17. 17.
    Gardos G (2005) Antipsychotic polypharmacy or monotherapy? Neuropsychopharmacol Hung 7(2):72–77PubMedGoogle Scholar
  18. 18.
    Sim K, Su A, Chan YH et al (2004) Clinical correlates of antipsychotic polytherapy in patients with schizophrenia in Singapore. Psychiatry Clin Neurosci 58(3):324–329PubMedCrossRefGoogle Scholar
  19. 19.
    Sim K, Su HC, Fujii S (2009) Low doses of antipsychotic drugs for hospitalized schizophrenia patients in East Asia: 2004 vs. 2001. Int J Neuropsychopharmacol 12(1):117–123PubMedCrossRefGoogle Scholar
  20. 20.
    American Psychiatric Association (2004) Practice guidelines for the treatment of patients with schizophrenia, Secondth edn. American Psychiatric Press, Washington, DCGoogle Scholar
  21. 21.
    Inagaki A (1999) Equivalent doses of psychotropics. Seiwa Shoten, TokyoGoogle Scholar
  22. 22.
    Overall JE (1962) The brief psychiatric rating scale. Psychol Rep 10:799–812CrossRefGoogle Scholar
  23. 23.
    Buchanan RW, Kreyenbuhl J, Zito JM et al (2002) The schizophrenia PORT pharmacological treatment recommendations: conformance and implications for symptoms and functional outcome. Schizophr Bull 28(1):63–73PubMedCrossRefGoogle Scholar
  24. 24.
    Lehman AF, Steinwachs DM (1998) Patterns of usual care for schizophrenia: initial results from the schizophrenia patient outcomes research team (PORT) client survey. Schizophr Bull 24(1):11–20, discussion 20–32PubMedCrossRefGoogle Scholar
  25. 25.
    Lehman AF, Steinwachs DM (1998) Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 24(1):1–10PubMedCrossRefGoogle Scholar
  26. 26.
    Sim K, Su A, Ungvari GS et al (2004) Depot antipsychotic use in schizophrenia: an East Asian perspective. Hum Psychopharmacol 19(2):103–109PubMedCrossRefGoogle Scholar
  27. 27.
    Patel MX, Haddad PM, Chaudhry IB et al (2010) Psychiatrists’ use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years. J Psychopharmacol 24(10):1473–1482PubMedCrossRefGoogle Scholar
  28. 28.
    Blackwell B (1973) Drug therapy: patient compliance. N Engl J Med 289(5):249–252PubMedCrossRefGoogle Scholar
  29. 29.
    Sacket DL (1978) Patients and therapies: getting the two together. N Engl J Med 298(5):278–279PubMedCrossRefGoogle Scholar
  30. 30.
    Hogan TP, Awad AG, Eastwood R (1983) A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 13(1):177–183PubMedCrossRefGoogle Scholar
  31. 31.
    Awad AG, Voruganti LN (2004) New antipsychotics, compliance, quality of life, and subjective tolerability – are patients better off? Can J Psychiatry 49(5):297–302PubMedGoogle Scholar
  32. 32.
    Mamo DC, Sweet RA, Chengappa KN et al (2002) The effect of age on the pharmacological management of ambulatory patients treated with depot neuroleptic medications for schizophrenia and related psychotic disorders. Int J Geriatr Psychiatry 17(11):1012–1017PubMedCrossRefGoogle Scholar
  33. 33.
    Adams CE, Fenton MK, Quraishi S et al (2001) Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 179:290–299PubMedCrossRefGoogle Scholar
  34. 34.
    Chong SA, Sachdev P, Mahendran R et al (2000) Neuroleptic and anticholinergic drug use in Chinese patients with schizophrenia resident in a state psychiatric hospital in Singapore. Aust N Z J Psychiatry 34(6):988–991PubMedCrossRefGoogle Scholar
  35. 35.
    Barnes TR, Curson DA (1994) Long-term depot antipsychotics. A risk-benefit assessment. Drug Saf 10(6):464–479PubMedCrossRefGoogle Scholar
  36. 36.
    Fenton WS, Blyler CR, Heinssen RK (1997) Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 23(4):637–651PubMedCrossRefGoogle Scholar
  37. 37.
    Coutinho E, Fenton M, Quraishi S (2009) Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses. Cochrane Database Syst Rev 2000(2):CD001164Google Scholar
  38. 38.
    Kane JM (2006) Utilization of long-acting antipsychotic medication in patient care. CNS Spectr 11(12 Suppl 14):1–7, quiz 7–8PubMedGoogle Scholar
  39. 39.
    Messer T, Glaser T, Landen H et al (2009) Long-term treatment with flupentixol results of a post-marketing surveillance study. J Psychopharmacol 23(7):805–813PubMedCrossRefGoogle Scholar
  40. 40.
    Patel MX, De Zoysa N, Bernadt M et al (2009) Depot and oral antipsychotics: patient preferences and attitudes are not the same thing. J Psychopharmacol 23(7):789–796PubMedCrossRefGoogle Scholar
  41. 41.
    Patel MX, de Zoysa N, Bernadt M et al (2008) A cross-sectional study of patients’ perspectives on adherence to antipsychotic medication: depot versus oral. J Clin Psychiatry 69(10):1548–1556PubMedCrossRefGoogle Scholar
  42. 42.
    Masand PS, Gupta S (2003) Long-acting injectable antipsychotics in the elderly: guidelines for effective use. Drugs Aging 20(15):1099–1110PubMedCrossRefGoogle Scholar
  43. 43.
    Lasser RA, Bossie C, Gharabawi G et al (2004) Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. Eur Psychiatry 19(4):219–225PubMedCrossRefGoogle Scholar
  44. 44.
    Singh D, O’Connor DW (2007) Depot risperidone in elderly patients: the experience of an Australian aged psychiatry service. Int Psychogeriatr 19(4):789–792PubMedCrossRefGoogle Scholar
  45. 45.
    Messer T, Tiltscher C, Schmauss M (2006) Polypharmacy in the treatment of schizophrenia. Fortschr Neurol Psychiatr 74(7):377–391PubMedCrossRefGoogle Scholar
  46. 46.
    Lerma-Carrillo I, de Pablo Bruhlmann S, del Pozo ML et al (2008) Antipsychotic polypharmacy in patients with schizophrenia in a brief hospitalization unit. Clin Neuropharmacol 31(6):319–332PubMedCrossRefGoogle Scholar
  47. 47.
    Kreyenbuhl JA, Valenstein M, McCarthy JF et al (2007) Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns. Psychiatr Serv 58(4):489–495PubMedCrossRefGoogle Scholar
  48. 48.
    Jaffe AB, Levine J (2003) Antipsychotic medication co prescribing in a large state hospital system. Pharmacoepidemiol Drug Saf 12(1):41–48PubMedCrossRefGoogle Scholar
  49. 49.
    Ito H, Koyama A, Higuchi T (2005) Polypharmacy and excessive dosing: psychiatrists’ perceptions of antipsychotic drug prescription. Br J Psychiatry 187:243–247PubMedCrossRefGoogle Scholar
  50. 50.
    (1999) The expert consensus guideline series. Treatment of schizophrenia. J Clin Psychiatry 60(Suppl 11): 3–80Google Scholar
  51. 51.
    Lehman AF, Steinwachs DM (2003) Evidence-based psychosocial treatment practices in schizophrenia: lessons from the patient outcomes research team (PORT) project. J Am Acad Psychoanal Dyn Psychiatry 31(1):141–154PubMedCrossRefGoogle Scholar
  52. 52.
    Miller AL, Chiles JA, Chiles JK et al (1999) The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms. J Clin Psychiatry 60(10):649–657PubMedCrossRefGoogle Scholar
  53. 53.
    National Institute for Clinical Excellence (2002) Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of Schizophrenia. Technology appraisal guidance. National Institute for Clinical Excellence, LondonGoogle Scholar
  54. 54.
    Goodwin G, Fleischhacker W, Arango C et al (2009) Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. Eur Neuropsychopharmacol 19(7):520–532PubMedCrossRefGoogle Scholar
  55. 55.
    Goren JL, Parks JJ, Ghinassi FA et al (2008) When is antipsychotic polypharmacy supported by research evidence? Implications for QI. Jt Comm J Qual Patient Saf 34(10):571–582PubMedGoogle Scholar
  56. 56.
    Glick ID, Pham D, Davis JM (2006) Concomitant medications may not improve outcome of antipsychotic monotherapy for stabilized patients with nonacute schizophrenia. J Clin Psychiatry 67(8):1261–1265PubMedCrossRefGoogle Scholar
  57. 57.
    Chong SA, Ravichandran N, Poon LY et al (2006) Reducing polypharmacy through the introduction of a treatment algorithm: use of a treatment algorithm on the impact on polypharmacy. Ann Acad Med Singapore 35(7):457–460PubMedGoogle Scholar
  58. 58.
    Kane JM (2006) Review of treatments that can ameliorate nonadherence in patients with schizophrenia. J Clin Psychiatry 67(Suppl 5):9–14PubMedGoogle Scholar
  59. 59.
    Kendell R, Jablensky A (2003) Distinguishing between the validity and utility of psychiatric diagnoses. Am J Psychiatry 160(1):4–12PubMedCrossRefGoogle Scholar
  60. 60.
    Rittmannsberger H (2002) The use of drug monotherapy in psychiatric inpatient treatment. Prog Neuropsychopharmacol Biol Psychiatry 26(3):547–551PubMedCrossRefGoogle Scholar
  61. 61.
    Stahl SM (1999) Antipsychotic polypharmacy, part 2: tips on use and misuse. J Clin Psychiatry 60(8):506–507PubMedCrossRefGoogle Scholar
  62. 62.
    Lieberman JA, Koreen AR, Chakos M et al (1996) Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry 57(Suppl 9):5–9PubMedGoogle Scholar
  63. 63.
    Ministry of Health (2011) Clinical practice guidelines: schizophrenia. Ministry of Health, SingaporeGoogle Scholar
  64. 64.
    Tranulis C, Skalli L, Lalonde P et al (2008) Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature. Drug Saf 31(1):7–20PubMedCrossRefGoogle Scholar
  65. 65.
    Davies L, Lewis S (2000) Antipsychotic medication for people with schizophrenia: an exploratory economic analysis of alternative treatment algorithms. University of York, Centre for Health Economics, YorkGoogle Scholar
  66. 66.
    Bagnall A-M, Jones L, Ginnelly L et al (2003) A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technol Assess 7(13):1–193PubMedGoogle Scholar
  67. 67.
    Davies LM, Jones PB, Barnes TRE et al (2007) Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. Br J Psychiatry 191:14–22PubMedCrossRefGoogle Scholar
  68. 68.
    Paton C, Lelliott P, Harrington M et al (2003) Patterns of antipsychotic and anticholinergic prescribing for hospital inpatients. J Psychopharmacol 17(2):223–229PubMedCrossRefGoogle Scholar
  69. 69.
    De Hert M, Wampers M, van Winkel R et al (2007) Anticholinergic use in hospitalised schizophrenic patients in Belgium. Psychiatry Res 152(2–3):165–172PubMedCrossRefGoogle Scholar
  70. 70.
    Acquaviva E, Gasquet I, Falissard B (2007) Antipsychotics dosage and antiparkinsonian prescriptions. Clin Pract Epidemiol Ment Health 3:14PubMedCrossRefGoogle Scholar
  71. 71.
    Clark RE, Bartels SJ, Mellman TA et al (2002) Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr Bull 28(1):75–84PubMedCrossRefGoogle Scholar
  72. 72.
    Magliano L, Fiorillo A, Guarneri M et al (2004) Prescription of psychotropic drugs to patients with schizophrenia: an Italian national survey. Eur J Clin Pharmacol 60(7):513–522PubMedCrossRefGoogle Scholar
  73. 73.
    Almond S, O’Donnell O (2000) Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol. Pharmacoeconomics 17(4):383–389PubMedCrossRefGoogle Scholar
  74. 74.
    Lewis M, McCrone P, Frangou S (2001) Service use and costs of treating schizophrenia with atypical antipsychotics. J Clin Psychiatry 62(10):749–756PubMedCrossRefGoogle Scholar
  75. 75.
    Lieberman JA, Stroup TS, McEvoy JP et al (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353(12):1209–1223PubMedCrossRefGoogle Scholar
  76. 76.
    Keefe RS, Silva SG, Perkins DO et al (1999) The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 25(2):201–222PubMedCrossRefGoogle Scholar
  77. 77.
    Weissman EM (2002) Antipsychotic prescribing practices in the veterans healthcare administration–New York metropolitan region. Schizophr Bull 28(1):31–42PubMedCrossRefGoogle Scholar
  78. 78.
    Bret P, Bret MC, Queuille E (2009) Prescribing patterns of antipsychotics in 13 French psychiatric hospitals. Encéphale 35(2):129–138PubMedCrossRefGoogle Scholar
  79. 79.
    Lieberman JA III (2004) Managing anticholinergic side effects. Prim Care Companion J Clin Psychiatry 6(Suppl 2):20–23PubMedGoogle Scholar
  80. 80.
    Tandon R, Belmaker RH, Gattaz WF et al (2008) World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res 100(1–3):20–38PubMedCrossRefGoogle Scholar
  81. 81.
    Lieberman JA III (2004) Metabolic changes associated with antipsychotic use. Prim Care Companion J Clin Psychiatry 6(Suppl 2):8–13PubMedGoogle Scholar
  82. 82.
    Baptista T, Kin NM, Beaulieu S et al (2002) Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 35(6):205–219PubMedCrossRefGoogle Scholar
  83. 83.
    Tandon R (2006) Comparing antipsychotic efficacy. Am J Psychiatry 163(9):1645PubMedCrossRefGoogle Scholar
  84. 84.
    Lin KM, Finder E (1983) Neuroleptic dosage for Asians. Am J Psychiatry 140(4):490–491PubMedGoogle Scholar
  85. 85.
    Lin KM, Poland RE, Nuccio I et al (1989) A longitudinal assessment of haloperidol doses and serum concentrations in Asian and Caucasian schizophrenic patients. Am J Psychiatry 146(10):1307–1311PubMedGoogle Scholar
  86. 86.
    Lin KM, Shen WW (1991) Pharmacotherapy for southeast Asian psychiatric patients. J Nerv Ment Dis 179(6):346–350PubMedCrossRefGoogle Scholar
  87. 87.
    Stahl SM, Grady MM (2004) A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Curr Med Chem 11(3):313–327PubMedCrossRefGoogle Scholar
  88. 88.
    Chen H, Kennedy WK, Dorfman JH et al (2007) The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia. Curr Med Res Opin 23(6):1351–1365PubMedCrossRefGoogle Scholar
  89. 89.
    Xiang YT, Weng YZ, Leung CM et al (2007) Exploring the clinical and social determinants of prescribing anticholinergic medication for Chinese patients with schizophrenia. Hum Psychopharmacol 22(3):173–180PubMedCrossRefGoogle Scholar
  90. 90.
    Ungvari GS, Chiu HF, Lam LC et al (1999) Gradual withdrawal of long-term anticholinergic antiparkinson medication in Chinese patients with chronic schizophrenia. J Clin Psychopharmacol 19(2):141–148PubMedCrossRefGoogle Scholar
  91. 91.
    Jones PB, Barnes TR, Davies L et al (2006) Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 63(10):1079–1087PubMedCrossRefGoogle Scholar
  92. 92.
    Gilbody S, Wahlbeck K, Adams C (2002) Randomized controlled trials in schizophrenia: a critical perspective on the literature. Acta Psychiatr Scand 105(4):243–251PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Yong K. H. Michael
    • 1
  • Norman Sartorius
    • 2
  • Kang Sim
    • 3
    • 4
  1. 1.Department of Psychological MedicineJurong Health Alexandra HospitalSingaporeSingapore
  2. 2.Association for the Improvement of Mental Health ProgrammesGenevaSwitzerland
  3. 3.Research at Institute of Mental Health (IMH)SingaporeSingapore
  4. 4.Yong Loo Lin School of MedicineNational University of SingaporeSingaporeSingapore

Personalised recommendations